BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cimzia (certolizumab pegol) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cimzia (certolizumab pegol)\, from Clinic
 alTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03152058-10@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cimzia (certolizumab pegol): Phase 2 readout est. (NCT03152058)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase 2.\nStudy: IMPACT Study: IM
 Prove Pregnancy in APS With Certolizumab Therapy\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 certolizumab-pegol#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03152058
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491913-10@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Cimzia (certolizumab pegol): Phase na readout est. (NCT07491913)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase na.\nStudy: Biologic Treatm
 ent Withdrawal in Takayasu Arteritis Patients in Sustained Remission\nEsti
 mated primary completion: 15 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/certolizumab-pegol#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07491913
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-10@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cimzia (certolizumab pegol): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase 3\, Rheumatoid Arthritis.\n
 Study: Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Respon
 se\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/certolizumab-pegol#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05930613-10@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Cimzia (certolizumab pegol): Phase 3 readout est. (NCT05930613)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase 3.\nStudy: Certolizumab in 
 Recurrent Implantation Failure (RIF)\nEstimated primary completion: April 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/certolizumab-pe
 gol#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05930613
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-10@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Cimzia (certolizumab pegol): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Cimzia (certolizumab pegol)\, phase 4\, Psoriasis.\nStudy: Util
 ization of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated pr
 imary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/certolizumab-pegol#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07352566
URL:https://assetmemo.bio/drug/certolizumab-pegol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
